Novel neuroprotective multicomponent therapy for amyotrophic lateral sclerosis designed by networked systems
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Herrando Grabulosa, Mireiaca
- dc.contributor.author Mulet, Rogerca
- dc.contributor.author Pujol, Albertca
- dc.contributor.author Mas, José Manuelca
- dc.contributor.author Navarro, Xavierca
- dc.contributor.author Aloy, Patrick, 1972-ca
- dc.contributor.author Coma Camprodón, Mireiaca
- dc.contributor.author Casas, Catyca
- dc.date.accessioned 2016-06-03T13:38:17Z
- dc.date.available 2016-06-03T13:38:17Z
- dc.date.issued 2016
- dc.description.abstract Amyotrophic Lateral Sclerosis is a fatal, progressive neurodegenerative disease characterized by loss of motor neuron function for which there is no effective treatment. One of the main difficulties in developing new therapies lies on the multiple events that contribute to motor neuron death in amyotrophic lateral sclerosis. Several pathological mechanisms have been identified as underlying events of the disease process, including excitotoxicity, mitochondrial dysfunction, oxidative stress, altered axonal transport, proteasome dysfunction, synaptic deficits, glial cell contribution, and disrupted clearance of misfolded proteins. Our approach in this study was based on a holistic vision of these mechanisms and the use of computational tools to identify polypharmacology for targeting multiple etiopathogenic pathways. By using a repositioning analysis based on systems biology approach (TPMS technology), we identified and validated the neuroprotective potential of two new drug combinations: Aliretinoin and Pranlukast, and Aliretinoin and Mefloquine. In addition, we estimated their molecular mechanisms of action in silico and validated some of these results in a well-established in vitro model of amyotrophic lateral sclerosis based on cultured spinal cord slices. The results verified that Aliretinoin and Pranlukast, and Aliretinoin and Mefloquine promote neuroprotection of motor neurons and reduce microgliosis.ca
- dc.description.sponsorship MHG was recipient of a postdoctoral fellowship from Fundació La marató-TV3 (#110430). This project has received funding from the European Union's Seventh Framework Programme for research, technological development and demonstration under grant agreement No. 306240. PA acknowledges financial support from the Spanish Ministerio de Ciencia e Innovación (BIO2013-48222), the European Commission (Agreement no: 306240) and the European Research Council (Agreements no: 614944). RM and MC are Anaxomics Biotech SL employees and JMM is founder and CEO of Anaxomics.
- dc.format.mimetype application/pdfca
- dc.identifier.citation Herrando-Grabulosa M, Mulet R, Pujol A, Mas JM, Navarro X, Aloy P et al. Novel neuroprotective multicomponent therapy for amyotrophic lateral sclerosis designed by networked systems. PLoS One. 2016; 11(1): e0147626. DOI 10.1371/journal.pone.0147626ca
- dc.identifier.doi http://dx.doi.org/10.1371/journal.pone.0147626
- dc.identifier.issn 1932-6203
- dc.identifier.uri http://hdl.handle.net/10230/26819
- dc.language.iso engca
- dc.publisher Public Library of Science (PLoS)ca
- dc.relation.ispartof PLoS One. 2016; 11(1): e0147626
- dc.rights © 2016 Herrando-Grabulosa et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.ca
- dc.rights.accessRights info:eu-repo/semantics/openAccessca
- dc.rights.uri http://creativecommons.org/licenses/by/4.0/ca
- dc.subject.other Medicamentsca
- dc.subject.other Biologia de sistemesca
- dc.title Novel neuroprotective multicomponent therapy for amyotrophic lateral sclerosis designed by networked systemsca
- dc.type info:eu-repo/semantics/articleca
- dc.type.version info:eu-repo/semantics/publishedVersionca